PharmAbcine

27 articles with PharmAbcine

• PharmAbcine to Present at H.C Wainwright Ophthalmology Virtual Conference

  7/26/2021

  PharmAbcine Inc. announced today that the company is invited to deliver a video presentation at H.C Wainwright Ophthalmology Virtual Conference on August 17, 2021 .

• PharmAbcine to Present at the BIO Digital International Convention 2021

  6/2/2021

  PharmAbcine Inc., a clinical-stage biotech company focusing on the development of antibody therapeutics, announced that the company will participate in BIO Digital International Convention.

• PharmAbcine Announces Encouraging Non-clinical Data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

  5/10/2021

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring non-clinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5 th . 

• PharmAbcine to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

  4/26/2021

   PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will present an e-poster featuring non-clinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.

• PharmAbcine presents the non-clinical data of PMC-309 at AACR 2021

  4/12/2021

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring the non-clinical data of PMC-309 at American Association for Cancer Research (AACR) 2021 Annual Meeting taking place virtually.

• PharmAbcine to Present at AACR Annual Meeting 2021

  3/11/2021

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today an e-poster presentation featuring nonclinical data of PMC-309 at American Association for Cancer Research (AACR) Annual Meeting.

• PharmAbcine to participate in BIO @ JPM and Biotech Showcase Digital during "J.P. Morgan Week 2021"

  1/4/2021

  - PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in BIO @ JPM and Biotech Showcase during the J.P. Morgan Week.

• PharmAbcine presents the latest data of the ongoing Phase Ib mTNBC trial at SABCS 2020

  12/9/2020

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today the presentation of the latest interim data from its ongoing phase Ib combination trial of olinvacimab and pembrolizumab for metastatic triple-negative breast cancer (mTNBC) pat

• PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020

  11/16/2020

  PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.

• PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020

  9/14/2020

  PharmAbcine Inc. (KOSDAQ: 208340ks) today announced positive data from its two combination trials of olinvacimab, its leading clinical candidate in oncology, with MSD's pembrolizumab at the 13th Annual Meeting of the Korean Society of Medical Oncology (KSMO 2020).

• PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its new 5,000L production line

  9/2/2020

  PharmAbcine (KRX: 208340ks), a biotech company focusing on the development of antibody therapeutics, announced on August 31 that it had signed a contract manufacturing organization(CMO) agreement with Binex, a leading biologics CDMO(Contract Development and Manufacturing Organization) company in Korea.

• PharmAbcine is presenting at the KSMO 2020

  9/2/2020

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotechnology company in South Korea, announced today that on September 4 th , the company will present the interim data of its ongoing IO combo clinical trials at KSMO 2020. KSMO 2020 is the 13th annual conference hosted by the Korean Society of Medical On

• PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC

  8/3/2020

   PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party's clinical candidate, olinvacimab and C-005, a 3 rd generation of EGFR inhibitor with superior brain-blood-barrier permeability, in treating non-small cell lung cance

• PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex

  6/26/2020

  PharmAbcine (KRX: 208340) (GM: Jin-san Yoo), biotech company focusing on the development of antibody therapeutics, announced on 18th that it had signed a contract manufacturing organization(CMO) agreement with biologics contract development and manufacturing organization (CDMO) Binex for additional production of investigationa

• PharmAbcine execute an agreement with Thermo Fisher for the development and manufacturing of its next-generation immune checkpoint blockade, PMC-309 for Phase I

  6/10/2020

  PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Thermo Fisher Scientific for the development and manufacturing of PMC-309, a next-generation immune checkpoint blockade to treat cancer.

• PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas

  6/3/2020

  PharmAbcine (KOSDAQ: 208340), a clinical-stage biotechnology company, announced today that the company entered into a license agreement with Wincal Biopharm ("Wincal"), a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the commercial value of PharmAbcine's existing and future assets through R&D efforts. U

• PharmAbcine to Participate in BIO Digital Conference

  5/27/2020

  The BIO International Convention is holding its annual event virtually this year amidst the COVID-19 global pandemic. The event brings together capital, scientific and development expertise needed to turn promising innovation into successful medicine.

• PharmAbcine to Present Preclinical Data of Blood Vessel Stabilizing PMC-402 at 2020 AACR Meeting

  5/19/2020

  PharmAbcine Inc. (KOSDAQ: 208340) announced today that it will present preclinical data of PMC-402, an active vessel stabilizing monoclonal antibody, at the 2020 American Association for Cancer Research (AACR).

• Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment

  4/6/2020

  Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline, a next generation therapeutic antibody candidate to treat oncology and neovascular disorders.

• PharmAbcine Announces Acceptance of Phase Ib Olinvacimab and Pembrolizuamb Combination Trial in rGBM Patients Abstract at the 2020 ASCO Annual Meeting

  4/3/2020

  PharmAbcine Inc. (KOSDAQ: 208340) announced today that the abstract summarizing interim data on its phase Ib trial of olinvacimab in combination with Merck’s anti-PD-1 antibody Keytruda® for recurrent glioblastoma multiforme (rGBM) patients has been accepted at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.